Milestones, scientific updates, and event appearances from Mito Laboratories. We share progress at a level appropriate for a seed-stage company.
Milestone ·
We are advancing a precision metabolic oncology strategy focused on glycolytic, LDHA-high / PDK1-high pancreatic tumors. The platform hypothesis is that simultaneous LDH + PDK1 inhibition induces mitochondrial stress that can be exploited via concurrent pan–anti-apoptotic Bcl-2 family inhibition, with a dose-sparing rationale for apoptotic activation.
Company ·
Mito Laboratories is seeking seed-stage capital and scientific collaborators to support in vitro synergy studies, metabolic subtype stratification, and provisional IP development for biomarker-defined combination therapy in PDAC.
Event ·
We will share confirmed conference appearances and scheduled meetings here. For investor or partner introductions, please contact us directly.
For background, summaries, or media requests, please email us. We do not share confidential or unpublished data via public channels.